Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2534 Target Snapshot

3-phosphoinositide-dependent protein kinase 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,962Compounds
510Assays
5Approved Drugs
3,188.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

3-phosphoinositide-dependent protein kinase 1 shows clinical signal disease relevance led by lymphoma. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O15530. Start with lymphoma, then reuse UniProt O15530 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with lymphoma, then reuse UniProt O15530 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
lymphoma

3-phosphoinositide-dependent protein kinase 1 shows clinical signal disease relevance led by lymphoma. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with lymphoma because it currently carries clinical signal support. Linked drugs include AR-12, UCN-01. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 3-phosphoinositide-dependent protein kinase 1 as ChEMBL target CHEMBL2534, mapped to UniProt O15530. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
3-phosphoinositide-dependent protein kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2534
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O15530
3-phosphoinositide-dependent protein kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 3-phosphoinositide-dependent protein kinase 1 is the right protein anchor across sources, using UniProt O15530 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why lymphoma is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name3-phosphoinositide-dependent protein kinase 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO15530
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label3-phosphoinositide-dependent protein kinase 1
UniProt AccessionO15530
Component TypeProtein
Sequence Length556 aa

3-phosphoinositide-dependent protein kinase 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 3-phosphoinositide-dependent protein kinase 1, mapped to UniProt O15530. Sequence length is 556 aa.

Mapped IDO15530
Review name3-phosphoinositide-dependent protein kinase 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

3-phosphoinositide-dependent protein kinase 1 shows clinical signal disease relevance led by lymphoma. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
lymphoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugAR-12
Linked drugUCN-01
Clinical signal Phase II
fallopian tube cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugUCN-01
Clinical signal Phase II
kidney cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugUCN-01
Clinical signal Phase II
melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugUCN-01
Clinical signal Phase II
ovarian cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugUCN-01
Clinical signal Phase II
pancreatic carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugUCN-01
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with lymphoma because it currently carries clinical signal support. Linked drugs include AR-12, UCN-01. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaselymphoma
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
5
Phase III
9
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC502,235.0
KI725.0
EC5033.0
KD195.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.26 IC50 0.556 Preclinical
CHEMBL1940246 9.22 Ki 0.6 Preclinical
CHEMBL1938415 9.22 Ki 0.6 Preclinical
CHEMBL1765751 9.2 IC50 0.631 Preclinical
CHEMBL1940251 9.15 Ki 0.7 Preclinical
CHEMBL1765750 9.1 IC50 0.7943 Preclinical
CHEMBL1940247 9.05 Ki 0.9 Preclinical
CHEMBL3644741 9.0 IC50 1.0 Preclinical
CHEMBL3644710 9.0 IC50 1.0 Preclinical
CHEMBL3644700 9.0 IC50 1.0 Preclinical
Distribution

pChEMBL Value Distribution

121
5.0
172
5.5
320
6.0
167
6.5
189
7.0
130
7.5
125
8.0
67
8.5
21
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
Properties Compare Identifier
Assay Landscape

Assay Landscape

510
Total Assays
1,165
Tested Compounds
3
Assay Types
Binding — 502 assays, 1,165 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 291 737 6.5
cell-based format 157 328 6.2
assay format 49 100 7.8
subcellular format 5 0 —
Functional — 7 assays, 157 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 13 6.5
assay format 2 144 6.3
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine